Speakers
Adam Lazorchak
Group Leader, Oncology & Immunopharmacology
EMD Serono
Day Two
10:15 am | Bintrafusp alfa, A Bifunctional Fusion Protein Simultaneously Blocking PD-L1 and TGF-ß in Tumor Microenvironment
David Evans
Chief Scientific Officer
Sirnaomics
Day One
12:30 pm | RNAi Therapeutics for Oncology: Silencing TGFb and Cox2 in HCC and NMSC
Paul Rennert
President & Chief Scientific Officer
Aleta Biotherapeutics
Day Two
3:00 pm | Fireside Chat: TGF-ß's Role in the Suppressive Function of T Cells in the TME - Challenges & Opportunities
Olaf Christensen
VP, Head of bintrafusp alfa, Global Development
EMD Serono
Day One
4:30 pm | Chair’s Closing Remarks
10:00 am | Chair's Opening Remarks
Day Two
4:45 pm | Chair’s Closing Remarks
10:00 am | Chair's Opening Remarks
Yan Lan
Senior Director in ImmunoOncology
EMD Serono
Shannon Turley
Senior Director, Cancer Immunology
Genentech
Day One
10:15 am | TGF-β’s Significance in the Cancer Immunotherapy Landscape
Yulei Wang
Principal Scientist, Oncology Biomarker Development
Genentech
Day One
3:30 pm | Clinical Biomarkers to Inform Therapeutic Development of TGF-ß Blockades in Immuno-Oncology
10:45 am | Panel Discussion: Debating the Best Approach to Target TGF-ß
Nadege Bercovici
CR1 – CNRS
Institut Cochin
Day One
4:00 pm | Evaluating TGF-ß Blockers in Combination Therapies: The Challenges of Preclinical Tumor Models
Bruce Rogers
Chief Scientific Officer
Morphic Therapeutic
Day One
1:30 pm | Round Table Discussion: Small Molecule Approach to Inhibiting the Moderation of TGF-ß
James Gulley
Chief, Genitourinary Malignancies Branch Head, Immunotherapy Group, GMB Director, Medical Oncology Service
Center for Cancer Research, NCI, NIH
Day Two
10:45 am | Bintrafusp alfa: It Takes Two To Tango
Julius Strauss
Co-Director Laboratory of Tumor Immunology and Biology
NCI
Viviana Cremasco
Senior Principal Scientist
Novartis
Day Two
1:00 pm | TGFβ-Blockade Uncovers Stromal Plasticity in Tumors by Revealing the Existence of a Novel Subset of Interferon- Licensed Fibr
Marc Pelletier
Translational Immune Oncology
Novartis
Day One
10:45 am | Panel Discussion: Debating the Best Approach to Target TGF-ß
Vuong Trieu
Chairman & CEO
Oncotelic
Day Two
3:45 pm | Antisense Agents in TGF-ß for Immuno-Oncology Drug Development
Christopher Heery
Chief Medical Officer
Precision BioSciences
Day Two
3:00 pm | Fireside Chat: TGF-ß's Role in the Suppressive Function of T Cells in the TME - Challenges & Opportunities
Aaron Martin
Senior Scientist, Cell Therapy Discovery
Precision BioSciences
Day Two
3:00 pm | Fireside Chat: TGF-ß's Role in the Suppressive Function of T Cells in the TME - Challenges & Opportunities
2:30 pm | Inhibition of TGF-ß Signaling in Gene-Edited Allogenic CAR-T Cells
Sharad Sharma
Senior Principal Scientist & Lab Head, Oncology Research
Sanofi
Day Two
12:00 pm | The Anti-TGFβ Neutralizing Antibody, SAR439459, Blocks the Immunosuppressive Effects of TGFβ & Inhibits the Growth of Syngeneic Tumors in Combination with anti-PD1
Thomas Schurpf
Associate Director
Scholar Rock
Day One
10:45 am | Panel Discussion: Debating the Best Approach to Target TGF-ß
Day Two
12:30 pm | Inhibition of TGFβ1 Activation with SRK-181 to Overcome Primary Resistance to Checkpoint Inhibition Therapy
Dori Thomas-Karyat
Chief Executive Officer
Synthis
Day Two
4:15 pm | Development of Immune Cell Targeted TGF-ß Therapies to Restore Tumor Clearance in Cancer Patients
Rick Gregory
Associate Director
Takeda Oncology
Day One
10:45 am | Panel Discussion: Debating the Best Approach to Target TGF-ß
Rosemary Akhurst
Professor
University of California San Francisco
Day One
3:00 pm | Understanding the Mechanisms of Action of TGF-ß Inhibition as Immunotherapy and How Somatic and Germline Genetics Influence Variable Responses Between Individuals
Rik Derynck
Professor - Departments of Cell, Tissue Biology & Anatomy
University of California San Francisco
Day One
10:45 am | Panel Discussion: Debating the Best Approach to Target TGF-ß
Sam Shrivastava
Chairman & CEO
Venn Therapeutics